食管癌切缘阳性患者的辅助性纳武单抗治疗：操之过急？ - Suppr

Suppr

超能文献

Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?

作者信息

Goense Lucas, van Hillegersberg Richard

机构信息

Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

Ann Surg Oncol. 2024 Jun;31(6):3567-3568. doi: 10.1245/s10434-024-15158-3. Epub 2024 Mar 8.

DOI:10.1245/s10434-024-15158-3

PMID:38457101

Abstract

摘要

相似文献

Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?

Ann Surg Oncol. 2024 Jun;31(6):3567-3568. doi: 10.1245/s10434-024-15158-3. Epub 2024 Mar 8.

[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].

Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.

Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.

Anticancer Res. 2024 Jan;44(1):185-193. doi: 10.21873/anticanres.16801.

The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.

J Gastrointest Surg. 2019 Sep;23(9):1729-1741. doi: 10.1007/s11605-018-04087-8. Epub 2019 Jan 22.

Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).

PLoS One. 2024 Apr 18;19(4):e0299742. doi: 10.1371/journal.pone.0299742. eCollection 2024.

ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.

Ann Surg Oncol. 2019 Dec;26(Suppl 3):802-803. doi: 10.1245/s10434-019-07728-7. Epub 2019 Oct 25.

Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.

Cancer Sci. 2020 May;111(5):1676-1684. doi: 10.1111/cas.14380. Epub 2020 Apr 29.

Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.

Future Oncol. 2020 Jun;16(17):1189-1198. doi: 10.2217/fon-2019-0821. Epub 2020 May 14.

[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].

Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.

[A Case of Long-Term Survival by Multidisciplinary Surgical Treatment for Metastatic Multi-Organ Metastasis after Radical Resection of Esophageal Cancer].

Gan To Kagaku Ryoho. 2022 Dec;49(13):1992-1994.

本文引用的文献

Adjuvant Therapy for Patients with a Tumor-Positive Resection Margin After Neoadjuvant Chemoradiotherapy and Esophagectomy.

Ann Surg Oncol. 2024 Jun;31(6):3813-3818. doi: 10.1245/s10434-024-14912-x. Epub 2024 Jan 20.

Adjuvant Therapy After Neoadjuvant Therapy for Esophageal Cancer: Who Needs It?

Ann Surg. 2023 Aug 1;278(2):e240-e249. doi: 10.1097/SLA.0000000000005679. Epub 2022 Aug 23.

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).

Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.

Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.

Br J Surg. 2020 Dec;107(13):1801-1810. doi: 10.1002/bjs.11864. Epub 2020 Sep 29.

The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis.

J Surg Res. 2020 May;249:82-90. doi: 10.1016/j.jss.2019.11.035. Epub 2020 Jan 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验